Overview
CYTK market data
Price History
CYTK price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.54 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.35 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,321.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $34.60 – $88.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.4B · P/B 15.68 · P/S 153.04.
Company News
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110Benzinga · Aug 13, 2026, 6:09 PM
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103Benzinga · Aug 13, 2026, 3:04 PM
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are InvalidBenzinga · Aug 13, 2026, 1:35 PM
8-K filing — CYTOKINETICS INC (CYTK)SEC EDGAR · Aug 13, 2026, 1:25 PM
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112Benzinga · Aug 10, 2026, 5:45 PM
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112Benzinga · Aug 7, 2026, 6:43 PM
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110Benzinga · Aug 7, 2026, 2:25 PM
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112Benzinga · Aug 7, 2026, 1:28 PM
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M EstimateBenzinga · Aug 6, 2026, 8:01 PM
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult PatientsBenzinga · Jul 30, 2026, 10:21 AM